trending Market Intelligence /marketintelligence/en/news-insights/trending/7rCv7iLXvybI90A5zEZ3zg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Investment consortium acquires majority stake in Russia-based JSC Pharmaceutical

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Investment consortium acquires majority stake in Russia-based JSC Pharmaceutical

An investment consortium acquired a 95.14% stake in Russian pharmaceutical company JSC Pharmaceutical Enterprise Obolenskoe from Alvansa Ltd. for a total investment of 15.5 billion Russian rubles.

The investment consortium includes Moscow-based diversified Russian holding company Sistema PJSFC, VTB Bank PJSC and members of the JSC Pharmaceutical management team. Alvansa is majority-owned by Gazprombank OJSC and UFG Private Equity.

According to a Dec. 28 news release, the companies made the investments via a joint holding company, Ristango Holding Ltd., and have signed a shareholder agreement securing rights of all of the investors to participate in the management of the business.

Sistema invested a total of 1.83 billion Russian rubles in the acquisition of JSC Pharmaceutical, giving it an effective stake of 11.7% in the pharmaceutical company.

In addition, Sistema and VTB signed an agreement under which Sistema will acquire VTB's stake in Ristango Holding within three years of the initial transaction.

The Russian Direct Investment Fund and its co-investors have reached an agreement with Sistema to consider participating in the transaction in early 2019 after additional study of the transaction terms and approval of the transaction terms by a consortium of investors headed by the fund.

JSC Pharmaceutical will be merged with Sistema portfolio company JSC Binnopharm. The combined company will operate four pharmaceutical production sites in Moscow and the Moscow region and will be established in the first half of 2019.

The combination of JSC Pharmaceutical and JSC Binnopharm will "create a unified company that is a top-10 Russian pharmaceutical company in the non-state sector with a diversified portfolio of over 200 products," Sistema stated in the news release. "Products that are leaders in their segments include vein tonic Venarus, the probiotic Maxilac and the liver protectant Urdoxa."

As of Dec. 27, US$1 was equivalent to 69.55 Russian rubles.